Investment analysts recommend two underperforming GLP-1 drug companies

Several financial publications have recommended two pharmaceutical companies as good investments: Novo Nordisk and Kailera Therapeutics. Both companies have performed poorly in the stock market recently, but analysts believe they could benefit from growing demand for GLP-1 medicines, which help people manage weight and diabetes.

Novo Nordisk is already a major player in the GLP-1 market. The company has faced setbacks over the past 18 months, but it is now developing a new drug called UBT251 with a partner company. Early studies have shown strong results.

Kailera Therapeutics is much smaller, with a total market value of $2.5 billion. Analysts see it as a company that could take business away from larger competitors like Eli Lilly.